Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06951841 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Name: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction — clinical trial record (NCT06951841)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorChina Medical University, China

Started2025-04-30

View on ClinicalTrials.gov ↗

Record status

This record was last updated April 30, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.

China Medical University, China

28 trials monitored

See all monitored trials

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Small Cell Lung Cancer

539 trials monitored

See 30 trials at risk

To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction

Trial Details

NCT Number	NCT06951841
Lead Sponsor	China Medical University, China
Conditions	Small Cell Lung Cancer
Enrollment	31 participants
Start Date	2025-04-30
Primary Completion	2026-05-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-04-30